Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 871-887

  Plé, Patrick A ^a   Green, Tim P ^a   Hennequin, Laurent F ^a   Curwen, Jon ^a   Fennell, Michael ^a   Allen, Jack ^a   Lambert Van Der Brempt, Christine ^a   Costello, Gerard ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINOQUINAZOLINE DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TYROSINE KINASE C SRC; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DOMAIN; STRUCTURE ANALYSIS; XENOGRAFT;

3T3 CELLS; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; DIOXOLES; MICE; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RATS, NUDE; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0842304432     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030317k     Document Type: Article

References (59)

1. (a) Brugge, J. S.; Erikson, R. L. Identification of a Transformation-specific Antigen Induced by Avian Sarcoma Virus. Nature 1977, 269, 346-348.
2. (b) Purchio, A. F.; Erikson, E.; Brugge, J. S.; Erikson, R. L. Identification of a Polypeptide Encoded by the Avian Sarcoma Virus Src Gene. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 1567-1571.
3. (c) Collett, M. S.; Erikson, R. L. Protein Kinase Activity Associated with the Avian Sarcoma Virus Src Gene Product. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 2021-2024.
4. (d) Hunter, T.; Sefton, B. M. Transforming Gene Product of Rous Sarcoma Virus Phosphorylates Tyrosine. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 1311-1315.
5. Lowe, C.; Yoneda, T.; Boyce, B. F.; Chen, H.; Mundy, G. R.; Sonano, P. Osteopetrosis in Src-deficient Mice is Due to an Autonomous Defect of Osteoclasts. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4485-4489.
6. c-src Protein Kinase Activity in Human Tumour Cell Lines and Tissues. J. Biol. Chem. 1986, 261, 13754-13759.
7. c-src Protein Kinase is an Early Event in Human Colon Carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1990, 84, 558-562.
8. (c) Talamonti, M. S.; Roh, M. S.; Curley, S. A.; Gallick, G. E. Increase in Activity and Level of pp60c-Src in Progressive Stages of Human Colorectal Cancer. J. Clin. Invest. 1993, 91, 3-60.
9. (d) Verbeek, B. S.; Vroom, T. M.; Adriaansen-Slot, S. S.; Ottenhoff-Kalff, A. E.; Geertzema, J. G.; Hennipman, A.; Rijksen, G. c-Src Protein Expression is Increased in Human Breast Cancer. An Immunohistochemical and Biochemical Analysis. J. Pathol. 1996, 180, 383-388.
10. (e) Lutz, M. P.; Esser, I. B.; Flossmann-Kast, B. B.; Vogelmann, R.; Luhrs, H.; Friess, H.; Buchler, M. W.; Adler, G. Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma. Biochem. Biophys. Res. Commun. 1998, 243, 503-508.
11. (f) Reissig, D.; Clement, J.; Sanger, J.; Berndt, A.; Kosmehl, H.; Bohmer, F. D. Elevated Activity and Expression of Src Family Kinases in Human Breast Carcinoma Versus Matched Non Tumour Tissue. J. Cancer Res. Clin. Oncol. 2001, 127, 226-230.
12. Boyer, B.; Valles, A. M.; Edmen N. Induction and Regulation of Epithelial-Mesenchymal Transitions. Biochem. Pharmacol. 2000, 60, 1091-1099.
13. (a) Irby, R. B.; Yeatman, T. J. Increased Src Activity Disrupts Cadherin/Catenin-mediated Homotypic Adhesion in Human Colon Cancer and Transformed Rodent Cells. Cancer Res. 2002, 62, 2669-2674.
14. (b) Avizienyte, E.; Wyke, A.; Jones, R. J.; McLean, G. W.; Westhoff, M. A.; Brunton, V. G.; Frame, M. C. Src-induced De-Regulation of E-cadherin in Colon Cancer Cells Requires Integrin Signalling. Nature Cell Biol. 2002, 4, 632-638.
15. Nam, J.-S.; Ino, Y.; Sakamoto, M.; Hirohashi, S. Src Family Kinase Inhibitor PP2 Restores the E-Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer Metastasis. Clin. Cancer Res. 2002, 8, 2430-2436.
16. (a) Fincham, V. J.; Frame, M. C. The Catalytic Activity of Src is Dispensable for Translocation to Focal Adhesions but Controls the Turnover of those Structures During Cell Motility. EMBO J. 1998, 17, 81-92.
17. (b) Frame, M. C. Src in Cancer: Deregulation and Consequences for Cell Behaviour. Biochim. Biophys. Acta 2002, 1602, 114-130.
18. Boyer, B.; Bourgeois, Y.; Poupon, M. F. Src Kinase Contributes to the Metastatic Spread of Carcinoma Cells. Oncogene 2002, 21, 2347-2356.
19. Allgayer, H.; Boyd, D. D.; Heiss, M. M.; Abdalla, E. K.; Curley, S. A.; Gallick, G. E. Activation of Src Kinase in Primary Colorectal Carcinoma: An Indicator of Poor Clinical Prognosis. Cancer 2002, 94, 344-351.
20. Wiener, J. R.; Widham, T. C.; Estrella, V. C.; Parikh, N. U.; Thall, P. F.; Deavers, M. T.; Bast, R. C.; Mills, G. B.; Gallick, G. E. Activated Src Protein Tyrosine Kinase is Overexpressed in Late-Stage Human Ovarian Cancers. Gynecol. Oncol. 2003, 88, 73-79.
21. Bénistant, C.; Chapuis, H.; Mottet, N.; Noletti, E.; Crapez, E.; Bali, J. P.; Roche, S. Deregulation of the Cytoplasmic Tyrosine Kinase c-Src in the Absence of a Truncating Mutation at Codon 531 in Human Bladder Carcinoma. Biochem. Biophys. Res. Commun. 2000, 273, 425-430.
22. (a) Metcalf, C. A., III; Van Schravendijk, M. R.; Dalgarno, D. C.; Sawyer, T. K. Targeting Protein Kinases for Bone Diseases: Discovery and Development of Src Inhibitors. Curr. Pharm. Des. 2002, 8, 2049-2075.
23. (b) Bohacek, R. S.; Dalgarno, D. C.; Hatada, M.; Jacobsen, V. A.; Lynch, B. A.; Macek, K. J.; Merry, T.; Metcalf, C. A., III; Narula, S. S.; Sawyer, T. K.; Shakespeare, W. C.; Violette, S. M.; Weigele, M. X-ray Structure of Citrate Bound to Src SH2 Leads to a High-Affinity, Bone-Targeted Src SH2 Inhibitor J. Med. Chem. 2001, 44, 660-666.
24. (c) Missbach, M.; Altmann, E.; Widler, L.; Susa, M.; Buchdunger, E.; Mett, H.; Meyer, T.; Green, J. Substituted 5,7-diphenyl-pyrrolo[2,3d]-pyrimidines: Potent Inhibitors of the Tyrosine Kinase c-Src. Bio. Med. Chem. Lett. 2000, 10, 945-949.
25. (d) Missbach, M.; Jeschke, M.; Feyen, J.; Müller, K.; Glatt, M.; Green, J.; Susa, M. A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo. Bone 1999, 24, 437-449.
26. (a) Schroeder, M. C.; Hamby, J. M.; Connolly, C. J. C.; Grohar, P. J.; Winters, R. T.; Barvian, M. R.; Moore, C. W.; Boushelle, S. L.; Crean, S. M.; Kraker, A. J.; Driscoll, D. L.; Vincent, P. W.; Elliott, W. L.; Lu, G. H.; Batley, B. L.; Dahring, T. K.; Major, T. C.; Panek, R. L.; Doherty, A. M.; Showalter, H. D. H. Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-yl Ureas. Structure-Activity Relationships against Selected Tyrosine Kinases and Exploration of In Vitro and In Vivo Anticancer Activity. J. Med. Chem. 2001, 44, 1915-1926.
27. c-src J. Med. Chem. 2000, 43, 3134-3147.
28. (c) Berger, D.; Dutia, M.; Powell, D.; Wissner, A.; DeMorin, F.; Raifeld, Y.; Weber, J.; Boschelli, F. Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src Kinase Inhibitors. Bio. Med. Chem. Lett. 2002, 12, 2989-2992 and references therein.
29. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Plé, P. A.; Lohmann, J.-J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
30. Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
31. Eissenstat, M. A.; Bell, M. R.; D'Ambra, T. E.; Alexander, E. J.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V.; Estep, K. G. Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics. J. Med. Chem. 1995, 38, 3094-3105.
32. Van Wijngaarden, I.; Kruse, C. G.; Van der Heyden, J. A. M.; Tulp, M. T. M. 2-Phenylpyrroles as Conformationally Restricted Benzamide Analogues. A New Class of Potential Antipsychotics. J. Med. Chem. 1988, 31, 1934-1940.
33. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 918-928.
34. Lespagnol, A.; Deprey, J. Dérivés Pyridaziniques. Bull. Soc. Chim. Fr. 1962, 1117-1120.
35. Gibson, K. H. Preparation of Haloanilinoquinazolines as Class I Receptor Tyrosine Kinase Inhibitors. PCT Int. Appl. 1996, WO 9633980, example 1 therein.
36. Adams, R. R.; Whitmore, F. C. Heterocyclic Basic Compounds. IV. 2-Aminoalkylamino-Pyridines. J. Am. Chem. Soc. 1945, 67, 735-738.
37. Hadri, A. E.; Leclerc, G. A. Convenient Synthesis of cis-4-(Sulfomethyl)-piperidin-2-carboxylic acid: NMR Assignment. J. Heterocycl. Chem. 1993, 30, 631-634.
38. (a) Hennequin, L. F. A.; Pie, P. Preparation of 4-anilinoquinazolines as Antitumor Agents. PCT Int. Appl. 2002, 44 pp. CODEN: PIXXD2 WO 0292579 A1 20021121 CAN 137:384857 AN 2002:888722 CAPLUS (Copyright 2003 ACS).
39. (b) Hennequin, L. F. A.; Ple, P. Preparation of 4-anilinoquinazolines as Antitumor Agents. PCT Int. Appl. 2002, 78 pp. CODEN: PIXXD2 WO 0292578 A1 20021121 CAN 137:384856 AN 2002:888721 CAPLUS (Copyright 2003 ACS).
40. (c) Hennequin, L. F. A.; Ple, P. Preparation of 4-anilinoquinazolines as Antitumor Agents. PCT Int. Appl. 2002, 96 pp. CODEN: PIXXD2 WO 0292577 A1 20021121 CAN 137:384855 AN 2002:888720 CAPLUS (Copyright 2003 ACS).
41. (d) Ple, P. Preparation of Antitumor Quinazolines. PCT Int. Appl. 2002, 73 pp. CODEN: PIXXD2 WO 0285895 A1 20021031 CAN 137:337908 AN 2002:832791 CAPLUS (Copyright 2003 ACS).
42. (e) Lambert, C. M.-P.; Ple, P. Preparation of 4-(indol-7-ylamino)quinazolines as Antitumor Agents. PCT Int. Appl. 2002, 70 pp. CODEN: PIXXD2 WO 0234744 A1 20020502 CAN 136:340694 AN 2002:332187 CAPLUS (Copyright 2003 ACS).
43. (f) Lambert, C. M.-P.; Ple, P. Preparation of 4-(4-benzofuranylamino)quinazolines as c-Src Tyrosine Kinase Inhibitors. PCT Int. Appl. 2002, 81 pp. CODEN: PIXXD2 WO 0230926 A1 20020418 CAN 136:325554 AN 2002:293648 CAPLUS (Copyright 2003 ACS).
44. (g) Lambert, C. M.-P.; Ple, P. Preparation of 4-(7-benzofuranylamino)quinazolines with Antitumor Activity. PCT Int. Appl. 2002, 92 pp. CODEN: PIXXD2 WO 0230924 A1 20020418 CAN 136:325553 AN 2002:293646 CAPLUS (Copyright 2003 ACS).
45. (h) Hennequin, L. F. A.; Ple, P.; Lambert, C. M.-P. Preparation of Quinazolines as an Anti-invasive Agent in the Containment and/or Treatment of Solid Tumor Disease. PCT Int. Appl. 2002, 138 pp. CODEN: PIXXD2 WO 0216352 A1 20020228 CAN 136:200201 AN 2002: 157764 CAPLUS (Copyright 2003 ACS).
46. Woodburn, A. J.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthorn, L. R. ZD1839, an Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Trial Development. Proc. Am. Assoc. Cancer Res. 1997, 38, 6633.
47. Not surprisingly, our Src inhibitors do not display a significant level of selectivity versus lck due to the very high sequence homology of these two enzymes (unpublished results).
48. Yamaguchi, H.; Hendrickson, W. A. Structural Basis for Activation of Human Lymphocyte Kinase Lck Upon Tyrosine Phosphorylation. Nature 1996, 384, 484-489.
49. Shewchuk, L.; Hassell, A.; Wisely, B.; Roeque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase. J. Med. Chem. 2000, 43, 133-138.
50. Corkery J. VIDA programme. OpenEye Scientific Software, 1999-2002.
51. McTigue, M. A.; Wiekersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russel, A. T.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. Structure 1999, 7, 319-330.
52. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-bromo-anilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 267-276.
53. Birch, A. M.; Bradley, P. A.; Gill, J. C.; Kerrigan, F.; Needham, P. L. N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methyl-amine Derivatives as D2 Antagonists/5-HT1A Partial Agonists with Potential as Atypical Antipsychotic Agents. J. Med. Chem. 1999, 42, 3342-3355.
54. Owa, T.; Yoshino, H.; Okauchi, T.; Yoshimatsu, K.; Ozawa, Y.; Sugi, N. H.; Nagasu, T.; Koyanagi, N.; Kitoh, K. Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle. J. Med. Chem. 1999, 42, 3789-3799.
55. Xu, W.; Harrison, S. C.; Eck, M. J. Three-Dimensional Structure of the Tyrosine Kinase 2 C-Src. Nature 1997, 385, 595-602.
56. Quanta; Molecular Simulations, Incorporated, 9685 Scranton Rd, San Diego, CA 92121-3752.
57. Momany, F. A.; Rone, R. Validation of the General Purpose QUANTA3.2/CHARMm force field. J. Comput. Chem. 1992, 13, 888-900.
58. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimisation, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
59. Pease, C. T.; Fennell, M.; Brewerton, D. A. Polymorphonuclear Leukocyte Motility in Men with Ankylosing Spondylitis. Ann. Rheum. Diseases 1989, 48, 35-41.